Yara Abdou, MD, on the Advantages of CAR Macrophages in Solid Tumors

The assistant professor of oncology at UNC School of Medicine discussed the first-in-human study being conducted with CT-0508.

"Another advantage of macrophages is that they're circulating cells and they migrate out of the blood within hours after the infusion. Therefore, the pro-inflammatory cytokines they released are not causing sustained elevation of cytokines in the blood and we don't see severe cytokine release syndrome with our macrophage therapy.”

A phase 1, first-in-human study is evaluating the safety, tolerability and preliminary efficacy of an anti-human epidermal growth factor receptor 2 (HER2) chimeric antigen receptor (CAR) macrophage therapy, CT-0508 (Carisma Therapeutics) in solid tumors with HER2 overexpression.

An overview of the study was presented at the American Society of Gene and Cell Therapy 25th Annual Meeting, May 16-19, 2022, in Washington, DC.by Yara Abdou, MD, assistant professor of oncology at University of North Carolina School of Medicine.

CGTLive spoke with Abdou to learn more about CT-0508 and how CAR macrophage therapies address the challenges of traditional CAR T-therapies in solid tumors. She discussed the progress of the first-in-human, phase 1 study in HER2+ solid tumors.

Stay up to date with coverage from ASGCT 2022 by clicking here.

REFERENCE
Abdou Y, Yuan Y, Ueno NT, et al. A phase 1, first in human (FIH) study of adenovirally transduced autologous macrophages engineered to contain an anti-HER2 chimeric antigen receptor (CAR) in subjects with HER2 overexpressing solid tumors. Presented at: ASGCT 25th Annual Meeting, May 16-19, 2022; Washington DC. Abstract #805
Related Videos
Binod Dhakal, MD, on Assessing Cilta-Cel in Lenalidomide-Refractory Multiple Myeloma
Brian Van Tine, MD, PhD, on Further Research With Cell Therapy in Synovial Sarcoma
Brian Van Tine, MD, PhD, on Continued Durability of Afami-Cel in Synovial Sarcoma
Thomas McCauley, PhD, on Treating Solid Tumors With Epigenomic Controllers
Rebecca Cottman, PhD, on Creating Regulated Gene Circuits to Enhance Cell Therapy Cytotoxicity
John Leonard, PhD, on an AAV Approach to Exon 51 Skipping in DMD
Related Content
© 2023 MJH Life Sciences

All rights reserved.